Stratification of risk based on immune signatures and prediction of the efficacy of immune checkpoint inhibitors in prostate cancer
Rattachement africain : cn, mo. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Prostate adenocarcinoma (PRAD) is a major threat to male health worldwide with a high mortality rate. New therapeutic strategies for the treatment of this malignant disease are of tremendous significance. Much attention has been paid to the involvement of immune cells in the prevention and treatment of cancer as well as how their regulatory systems contribute to effective cancer treatment. In this study, we constructed prognostic immune profiles based on The Cancer Genome Atlas (TCGA)-PRAD data sets and tested their predictive power on total and internal data sets. Then, we looked at how the lymphocyte of tumor invasion varied between the high-risk group and the low-risk group. Five immune-related genes made up the immune marker, which was an independent predictive factor in patients with PRAD. Patients in the low-risk score group had a higher rate of overall survival and a stronger infiltration of immune cells in the tumor microenvironment, which was highly related to clinical outcomes but required prospective validation.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Stratification of risk based on immune signatures and prediction of the efficacy of immune checkpoint inhibitors in prostate cancer
- Date Crossref
- 01/01/2023
- Éditeur
- MRE Press
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine Department of Oncology pays non établi dans la noticeÉtablissement de santé
-
Nantong University Department of Clinical Biobank & Institute of Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Affiliated Hospital of Nantong University pays non établi dans la noticeÉtablissement de santé
-
University of Macau pays non établi dans la noticeUniversité ou école supérieure
-
Department of Clinical Biobank & pays non établi dans la noticeÉtablissement de santé
-
Faculty of Health Sciences Centre for Precision Medicine Research and Training pays non établi dans la noticeUniversité ou école supérieure
Department of Oncology — First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Department of Clinical Biobank & Institute of Oncology — Nantong University et Affiliated Hospital of Nantong University, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.